



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Seffalair Spiromax

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IB/0001	B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	15/07/2021		SmPC and PL	B.II.f.1.b.1 - Extension of the shelf life of the finished product as packaged for sale from 18 months to 24 months. Furthermore, local representatives have been amended for Malta, Spain, Ireland, Greece and United Kingdom (Northern Ireland).

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

